Publications by authors named "Anthea Monod"
Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding of the tumor immune microenvironment (TIME) is required to stratify patients and identify factors leading to therapy resistance. We previously identified that the melanoma immune profile (MIP), an IFN-based gene signature, and the ratio of CD8 cytotoxic T lymphocytes (CTL) to CD68 macrophages both predict disease-specific survival (DSS).
View Article and Find Full Text PDFArticle Synopsis
- The study emphasizes the need for improved analysis methods of the tumor microenvironment (TME) to better stratify melanoma patients for immunotherapy, moving beyond traditional TIL analysis.
- Researchers utilized quantitative multiplex immunofluorescence (qmIF) to evaluate the proximity of cytotoxic lymphocytes (CTLs) and macrophages in melanoma tumors, finding that CTLs were significantly closer to activated macrophages than to nonactivated ones.
- Results indicated that higher CTL density and lower macrophage density in the tumor stroma correlated with better disease-specific survival, suggesting that the CTL/macrophage ratio could serve as a potential biomarker for predicting patient outcomes in melanoma treatment.